ATE94387T1 - Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung. - Google Patents
Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.Info
- Publication number
- ATE94387T1 ATE94387T1 AT91400163T AT91400163T ATE94387T1 AT E94387 T1 ATE94387 T1 AT E94387T1 AT 91400163 T AT91400163 T AT 91400163T AT 91400163 T AT91400163 T AT 91400163T AT E94387 T1 ATE94387 T1 AT E94387T1
- Authority
- AT
- Austria
- Prior art keywords
- myristoyl
- phenylalanine
- diseases
- treatment
- myristoylation
- Prior art date
Links
- GFNNQTYRJPFJGX-NRFANRHFSA-N (2s)-3-phenyl-2-(tetradecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GFNNQTYRJPFJGX-NRFANRHFSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000007498 myristoylation Effects 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000834A FR2657259A1 (fr) | 1990-01-25 | 1990-01-25 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE94387T1 true ATE94387T1 (de) | 1993-10-15 |
Family
ID=9393082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91400163T ATE94387T1 (de) | 1990-01-25 | 1991-01-25 | Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5164414A (enExample) |
| EP (1) | EP0443891B1 (enExample) |
| JP (1) | JPH0717503B2 (enExample) |
| AT (1) | ATE94387T1 (enExample) |
| AU (1) | AU633395B2 (enExample) |
| CA (1) | CA2034861A1 (enExample) |
| DE (1) | DE69100364T2 (enExample) |
| DK (1) | DK0443891T3 (enExample) |
| ES (1) | ES2060310T3 (enExample) |
| FR (1) | FR2657259A1 (enExample) |
| IE (1) | IE65573B1 (enExample) |
| OA (1) | OA09478A (enExample) |
| PT (1) | PT96571A (enExample) |
| ZA (1) | ZA91574B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672598A1 (fr) * | 1991-02-11 | 1992-08-14 | Adir | Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5599947A (en) * | 1993-01-14 | 1997-02-04 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5859052A (en) * | 1993-01-14 | 1999-01-12 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US6407125B1 (en) | 1995-12-29 | 2002-06-18 | Novactyl, Inc. | Pharmacological agent and method of treatment |
| US6743771B2 (en) | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US6127393A (en) | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US6579891B1 (en) | 1995-12-29 | 2003-06-17 | Novactyl, Inc. | Agent and method for prevention and treatment of cancer in animals |
| US6441009B1 (en) | 1998-08-01 | 2002-08-27 | Novactyl, Inc. | Agent and method of preventing and treating heavy metal exposure and toxicity |
| CA2704975A1 (en) * | 1999-10-13 | 2001-05-31 | Marco A. Chacon | Therapeutic intervention to mimic the effect of caloric restriction |
| US6403618B1 (en) | 2000-02-15 | 2002-06-11 | Novactyl, Inc. | Agent and method for controlling angiogenesis |
| WO2003007876A2 (en) * | 2001-06-25 | 2003-01-30 | University Of Massachusetts | N-fatty acid-amino acid conjugates and therapeutic uses |
| DE10353806A1 (de) * | 2003-11-14 | 2005-07-07 | Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten | Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren |
| US7544714B2 (en) * | 2004-07-16 | 2009-06-09 | University Of Massachusetts | Lipid-amino acid conjugates and methods of use |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| WO2013013302A1 (en) * | 2011-07-22 | 2013-01-31 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
| KR102045589B1 (ko) | 2012-03-30 | 2019-11-15 | 지보당 에스아 | 식품 향미 화합물로서의 n-아실-아미노산 유도체 |
| EP2830441B1 (en) | 2012-03-30 | 2019-11-13 | Givaudan SA | N-acyl derivatives of gamma amino-butyric acid as food flavouring compounds |
| EP2830438B1 (en) | 2012-03-30 | 2019-09-04 | Givaudan SA | N-acyl derivatives of gamma amino-butyric acid as food flavouring compounds, powder compositions containing them |
| WO2013149022A1 (en) | 2012-03-30 | 2013-10-03 | Givaudan S.A. | N-acyl proline derivatives as food flavouring compounds |
| SG11201405295WA (en) | 2012-03-30 | 2014-11-27 | Givaudan Sa | N-acyl-amino acid derivatives for improvement of the flavour profile edible|compositions |
| CN104244734B (zh) | 2012-03-30 | 2018-04-03 | 奇华顿股份有限公司 | 作为食品加香化合物的n‑酰化1‑氨基环烷基羧酸 |
| SG11201405340XA (en) | 2012-03-30 | 2014-10-30 | Givaudan Sa | N-acylated methionine derivatives as food flavouring compounds |
| SG10201703505VA (en) * | 2012-10-30 | 2017-06-29 | Pacylex Pharmaceuticals Inc | Synthetic lethality and the treatment of cancer |
| GB201317424D0 (en) | 2013-10-02 | 2013-11-13 | Givaudan Sa | Improvements in or relating to organic compounds |
| WO2015050534A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| US20160227825A1 (en) | 2013-10-02 | 2016-08-11 | Givaudan Sa | Organic Compounds having Taste-Modifying Properties |
| WO2015048990A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan Sa | Organic compounds having taste-modifying properties |
| WO2015050535A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| CN105592719B (zh) * | 2013-10-02 | 2020-03-10 | 奇华顿股份有限公司 | 有机化合物 |
| WO2015050537A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| WO2015050536A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | N-acylated 2-aminoisobutyric acid compounds and flavour compositions containing them |
| WO2017011907A1 (en) | 2015-07-17 | 2017-01-26 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778878A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides I |
| US4778877A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides II |
-
1990
- 1990-01-25 FR FR9000834A patent/FR2657259A1/fr active Granted
-
1991
- 1991-01-24 US US07/645,124 patent/US5164414A/en not_active Expired - Fee Related
- 1991-01-24 CA CA002034861A patent/CA2034861A1/fr not_active Abandoned
- 1991-01-24 PT PT96571A patent/PT96571A/pt not_active Application Discontinuation
- 1991-01-24 JP JP3007188A patent/JPH0717503B2/ja not_active Expired - Lifetime
- 1991-01-24 IE IE24291A patent/IE65573B1/en not_active IP Right Cessation
- 1991-01-25 EP EP91400163A patent/EP0443891B1/fr not_active Expired - Lifetime
- 1991-01-25 OA OA59940A patent/OA09478A/xx unknown
- 1991-01-25 AT AT91400163T patent/ATE94387T1/de active
- 1991-01-25 DE DE91400163T patent/DE69100364T2/de not_active Expired - Fee Related
- 1991-01-25 DK DK91400163.1T patent/DK0443891T3/da active
- 1991-01-25 ZA ZA91574A patent/ZA91574B/xx unknown
- 1991-01-25 ES ES91400163T patent/ES2060310T3/es not_active Expired - Lifetime
- 1991-01-25 AU AU69987/91A patent/AU633395B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IE910242A1 (en) | 1991-07-31 |
| PT96571A (pt) | 1991-10-15 |
| ZA91574B (en) | 1991-11-27 |
| OA09478A (fr) | 1992-11-15 |
| JPH04210916A (ja) | 1992-08-03 |
| AU6998791A (en) | 1991-08-01 |
| AU633395B2 (en) | 1993-01-28 |
| US5164414A (en) | 1992-11-17 |
| CA2034861A1 (fr) | 1991-07-26 |
| EP0443891A1 (fr) | 1991-08-28 |
| DE69100364D1 (de) | 1993-10-21 |
| DK0443891T3 (da) | 1993-12-27 |
| ES2060310T3 (es) | 1994-11-16 |
| DE69100364T2 (de) | 1994-04-21 |
| IE65573B1 (en) | 1995-11-01 |
| JPH0717503B2 (ja) | 1995-03-01 |
| EP0443891B1 (fr) | 1993-09-15 |
| FR2657259A1 (fr) | 1991-07-26 |
| FR2657259B1 (enExample) | 1994-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE94387T1 (de) | Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung. | |
| ATE76294T1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| DE69109560D1 (de) | Fungizide Zusammensetzung zur Behandlung von Saatgut. | |
| DE3856594D1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
| DE122005000002I1 (de) | Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz. | |
| DE69229944D1 (de) | Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen | |
| ATE191849T1 (de) | Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst | |
| ATE137116T1 (de) | Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen | |
| DE69233725D1 (de) | Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren | |
| ATE83378T1 (de) | Verwendung von 3'-azido-deoxythymidin zur herstellung eines arzneimittels zur behandlung von humanen brustcarzinomen. | |
| ATE174798T1 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
| DE69110779D1 (de) | Schilddrüsenhormone zur kardialen behandlung. | |
| DE69232911D1 (de) | Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen | |
| ATE209914T1 (de) | Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen | |
| DE69313261D1 (de) | Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS | |
| DE69007065D1 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
| DE69026511D1 (de) | Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis | |
| NO913117L (no) | Fremgangsmaate for behandling av benoedeleggende sykdommer. | |
| DE3873188D1 (de) | Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen. | |
| DE69124415D1 (de) | Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen | |
| DE69300037D1 (de) | Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. | |
| DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
| DE69228235D1 (de) | Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen |